BlueRock Therapeutics has dosed the first patient in its pivotal phase 3 trial of bemdaneprocel, an investigational cell therapy for Parkinson’s disease. The exPDite-2 study is the first phase 3 trial of an allogeneic pluripotent stem cell derived therapy for the condition. Secondary endpoints will evaluate movement, non-motor symptoms, safety and tolerability, alongside measures of daily living and quality of life. The trial builds on phase 1 data showing good tolerability and encouraging trends in motor function at 24 months post-surgery. Its pipeline includes bemdaneprocel for Parkinson’s and OpCT-001 for photoreceptor disorders.